Jetrea: Does it work?

Poster Details

First Author: M.Siddique UK

Co Author(s):    I. Khan   M. Musadiq                          

Abstract Details


To evaluate the efficacy and side effects of intravitreal ocriplasmin


Hospital Based, Interventional study


Suitable patients were identified for intravitreal Jetrea. Patients with VMT and stage 2 macular holes were included. ERM was an exclusion. OCT was performed on the day of injection to see if they still need injection or not.


We identified 12 patients out of which 2 settled without injection. Ten patients needed injection and 60 percent got VMT released in 28 days. No side effects were noted.


Ocriplasmin is a good treatment for VMT and stage 2 macular holes.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy